{"id":"azd0292","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Musculoskeletal pain"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K delta subunit, AZD0292 is thought to modulate the immune response and potentially treat various conditions.","oneSentence":"AZD0292 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:50.814Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia"},{"name":"Relapsed or refractory non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT07088926","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-06","conditions":"Bronchiectasis With Pseudomonas Aeruginosa Colonization","enrollment":435},{"nctId":"NCT07222254","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-12","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT06311760","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-09","conditions":"Healthy Participants Study","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD0292","genericName":"AZD0292","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD0292 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia, Relapsed or refractory non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}